학술논문
Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States
Document Type
article
Author
Tenforde, Mark W; Self, Wesley H; Zhu, Yuwei; Naioti, Eric A; Gaglani, Manjusha; Ginde, Adit A; Jensen, Kelly; Talbot, H Keipp; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; Gibbs, Kevin W; Files, D Clark; Hager, David N; Shehu, Arber; Prekker, Matthew E; Erickson, Heidi L; Gong, Michelle N; Mohamed, Amira; Johnson, Nicholas J; Srinivasan, Vasisht; Steingrub, Jay S; Peltan, Ithan D; Brown, Samuel M; Martin, Emily T; Monto, Arnold S; Khan, Akram; Hough, Catherine L; Busse, Laurence W; ten Lohuis, Caitlin; Duggal, Abhijit; Wilson, Jennifer G; Qadir, Nida; Chang, Steven Y; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M; Kwon, Jennie H; Exline, Matthew C; Botros, Mena M; Lauring, Adam S; Shapiro, Nathan I; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Rice, Todd W; Jones, Ian D; Stubblefield, William B; Baughman, Adrienne; Womack, Kelsey N; Rhoads, Jillian P; Lindsell, Christopher J; Hart, Kimberly W; Turbyfill, Caitlin; Olson, Samantha; Murray, Nancy; Adams, Katherine; Patel, Manish M
Source
Clinical Infectious Diseases. 76(3)
Subject
Language
Abstract
BackgroundCoronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were authorized in the United States in December 2020. Although vaccine effectiveness (VE) against mild infection declines markedly after several months, limited understanding exists on the long-term durability of protection against COVID-19-associated hospitalization.MethodsCase-control analysis of adults (≥18 years) hospitalized at 21 hospitals in 18 states 11 March-15 December 2021, including COVID-19 case patients and reverse transcriptase-polymerase chain reaction-negative controls. We included adults who were unvaccinated or vaccinated with 2 doses of a mRNA vaccine before the date of illness onset. VE over time was assessed using logistic regression comparing odds of vaccination in cases versus controls, adjusting for confounders. Models included dichotomous time (